EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Continuous Glucose Monitoring–Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4

Harpreet S Bajaj iD, Björg Ásbjörnsdóttir iD, Lisbeth Carstensen iD, Christian Laugesen iD, Chantal Mathieu iD, Athena Philis-Tsimikas iD, Tadej Battelino iD

Diabetes Care · 2024

DOI: 10.2337/dc23-2136 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, 2024. Verfasst von Harpreet S Bajaj und 6 weiteren Autor:innen. Beteiligte Einrichtung: LMC Diabetes and Endocrinology, Brampton, Ontario, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemia, Insulin, Long-Acting. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE This post hoc analysis assessed continuous glucose monitoring (CGM)–based metrics and hypoglycemia duration with once-weekly insulin icodec versus once-daily basal insulin analogs in insulin-experienced individuals with long-standing type 2 diabetes from two 26-week phase 3a trials (ONWARDS 2 and ONWARDS 4). RESEARCH DESIGN AND METHODS Time in range (TIR) (3.9–10.0 mmol/L), time above range (TAR) (>10.0 mmol/L), and time below range (TBR) (<3.9 mmol/L and <3.0 mmol/L) were assessed during three CGM time periods (switch [weeks 0–4], end of treatment [weeks 22–26], and follow-up [weeks 27–31]) for icodec versus comparators (ONWARDS 2, insulin degludec [basal regimen]; ONWARDS 4, insulin glargine U100 [basal-bolus regimen]) using double-blind CGM data. CGM-derived hypoglycemic episode duration (<3.9 mmol/L) was assessed. RESULTS In both trials, there were no statistically significant differences in TIR, TAR, or TBR (<3.0 mmol/L) for icodec versus comparators across all time periods. In the end-of-treatment period, mean TIR was 63.1% (icodec) vs. 59.5% (degludec) in ONWARDS 2 and 66.9% (icodec) vs. 66.4% (glargine U100) in ONWARDS 4. Mean TBR <3.9 mmol/L and <3.0 mmol/L remained within recommended targets (<4% and <1%, respectively) across time periods and treatment arms. Hypoglycemic episode duration (<3.9 mmol/L) was comparable across time periods and treatment arms (median duration ≤40 min). CONCLUSIONS In insulin-experienced participants with long-standing type 2 diabetes, CGM-based TIR, TAR, and CGM-derived hypoglycemia duration (<3.9 mmol/L) were comparable for icodec and once-daily basal insulin analogs during all time periods. TBR remained within recommended targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HypoglycemiaInsulin, Long-ActingHumansInsulinHypoglycemic AgentsBlood GlucoseBlood Glucose Self-MonitoringContinuous Glucose MonitoringInsulin GlargineInsulin, Regular, Human

Substanzen

insulin icodecInsulinHypoglycemic AgentsBlood GlucoseInsulin GlargineInsulin, Regular, HumanInsulin, Long-Acting

Autor:innen und Institutionen

  • LMC Diabetes and Endocrinology, Brampton, Ontario, Canada.
  • Novo Nordisk A/S, Søborg, Denmark.
  • Clinical and Experimental Endocrinology, University of Leuven, Leuven, Belgium.
  • Scripps Whittier Diabetes Institute, San Diego, CA.
  • University Medical Centre Ljubljana, Ljubljana, Slovenia.
  • Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

ORCID-Profile: Harpreet S Bajaj, Björg Ásbjörnsdóttir, Lisbeth Carstensen, Christian Laugesen, Chantal Mathieu, Athena Philis-Tsimikas, Tadej Battelino

Förderung

  • NIDDK NIH HHS
  • Novo Nordisk A/S

Zitieren

APA

Bajaj, H. S., Ásbjörnsdóttir, B., Carstensen, L., Laugesen, C., Mathieu, C., Philis-Tsimikas, A., & Battelino, T. (2024). Continuous Glucose Monitoring–Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4. Diabetes Care. https://doi.org/10.2337/dc23-2136

Vancouver

Bajaj HS, Ásbjörnsdóttir B, Carstensen L, Laugesen C, Mathieu C, Philis-Tsimikas A, et al. Continuous Glucose Monitoring–Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4. Diabetes Care. 2024. doi:10.2337/dc23-2136

BibTeX
@article{Bajaj2024,
  author = {Bajaj, Harpreet S and Ásbjörnsdóttir, Björg and Carstensen, Lisbeth and Laugesen, Christian and Mathieu, Chantal and Philis-Tsimikas, Athena and Battelino, Tadej},
  title = {Continuous Glucose Monitoring–Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4},
  journal = {Diabetes Care},
  year = {2024},
  doi = {10.2337/dc23-2136}
}
Kostenlos starten →